1.29
-0.08(-5.84%)
Currency In USD
| Previous Close | 1.37 |
| Open | 1.4 |
| Day High | 1.4 |
| Day Low | 1.28 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.91 |
| Volume | 79,674 |
| Average Volume | 131,883 |
| Market Cap | 76.42M |
| PE | -2.87 |
| EPS | -0.45 |
| Moving Average 50 Days | 1.35 |
| Moving Average 200 Days | 1.2 |
| Change | -0.08 |
If you invested $1000 in Vivani Medical, Inc. (VANI) 10 years ago, it would be worth $5.61 as of September 08, 2025 at a share price of $1.29. Whereas If you bought $1000 worth of Vivani Medical, Inc. (VANI) shares 5 years ago, it would be worth $589.04 as of September 08, 2025 at a share price of $1.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
GlobeNewswire Inc.
Sep 04, 2025 12:30 PM GMT
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
GlobeNewswire Inc.
Aug 20, 2025 12:30 PM GMT
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mend
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
GlobeNewswire Inc.
Aug 05, 2025 12:10 PM GMT
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study’s primary objectives New NPM-139 (semagl